Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR - Wikidata - wikimedia - TriplyDB

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

http://www.wikidata.org/entity/Q29547545

about

Icotinib is an active treatment of non-small-cell lung cancer: a retrospective study Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer Third-line systemic treatment for non-small cell lung cancer First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer Targeted therapies and immunotherapy in non-small-cell lung cancer Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer FGFR3-TACC3 fusion in solid tumors: mini review New targeted treatments for non-small-cell lung cancer - role of nivolumab Molecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future Directions Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer The steady progress of targeted therapies, promising advances for lung cancer Afatinib in Non-Small Cell Lung Cancer Gene aberrations for precision medicine against lung adenocarcinoma Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives Pulmonary Toxicities of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials Somatic DNA mutation analysis in targeted therapy of solid tumours Role of FNAC, fluid specimens, and cell blocks for cytological diagnosis of lung cancer in the present era Treatment of advanced squamous cell carcinoma of the lung: a review China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version)China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version)Clinical development of nintedanib for advanced non-small-cell lung cancer Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemoprevention Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer Novel targeted agents for the treatment of lung cancer in China The Evolution of Therapies in Non-Small Cell Lung Cancer Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application

P2860

Q21132047-B064EC06-0F1D-4BDF-8D6A-2A911CB8F653 Q21132357-8EE2BCE0-6145-4C0E-BDAA-9809541B6208 Q21198843-62753385-12BC-4EB8-877C-FA78AB737B98 Q24187743-0BD548A7-B4A6-4ED4-9A2D-6E6B653EA45F Q24194090-8EB8A0DF-D533-407E-AED1-F6BC84C9BCD2 Q24201207-BC368724-22EB-447C-B1BC-21FC73266B52 Q24304423-86013152-657E-4F0C-9152-9FC028BCDFDB Q24606177-D19401A0-00D5-487B-8F4D-EDDC6169D986 Q24611043-6C0FD684-9FC5-4C49-84D5-58EFB20512F5 Q26471909-EEC4E008-7446-4022-B8FF-505F89BE61A0 Q26738986-266DDDBB-C2AF-4C96-A79D-4E66DCF3E5DB Q26739096-21F9BB10-6701-464F-8ADD-4294B276C6D0 Q26740529-33E9B426-2793-4AAB-8F4C-C63069713805 Q26740578-25A455E9-BB79-46F5-B2A0-22A6BA342F8C Q26740988-07668B29-E8D2-4FD4-AD00-E22251562E2E Q26741320-82651799-A2C8-4B48-B603-4680018BB9B4 Q26741814-72D62CA8-5CDC-4CD5-8657-29EBC8400807 Q26744284-CF5B6813-3856-4AF2-AD02-7A6E1252A058 Q26744339-CD827D50-F0BC-4FAE-AA06-081F4BCA13B6 Q26745427-5DE718B9-CFE9-41BB-82C2-1313892AD12D Q26746895-C87ECAA1-280C-4453-86E3-C7D4B05E3FBD Q26749005-13767F06-B624-495F-84C4-61A628E3DCB2 Q26749348-C170742C-3BF4-41EA-B24D-FF83F0678C87 Q26751274-FFFD008B-FC5B-425B-A128-9E9D2971153C Q26768125-A8C5F529-4CB5-407F-B771-3F4A0B876AB1 Q26770324-56BC55C3-659A-4785-8673-BA7009AA63AD Q26774726-BB85E726-F58F-4A9B-82EE-18EC672CD3B2 Q26775392-990055CF-78D0-4674-8498-1A74543082FA Q26775603-038BFD58-5B45-4C73-BA1A-A51A2E02A151 Q26775677-7430CAD5-C271-40BF-8BD7-3A8B87A17CCB Q26775822-06B6ADFB-0C93-4496-9B40-31074C9CED4E Q26778318-DE585096-8EF3-4515-AD28-552862D5924F Q26781662-99E1576F-B2C7-4815-B847-7CE22BA805B8 Q26781810-E67B2714-9A27-456F-BF09-0E385BD54157 Q26782809-961A9659-E552-4569-A4B4-13D843181722 Q26784298-A7536F57-6290-4D81-833B-8697425921F8 Q26786580-57B7AE54-778C-4615-AC9A-F7FF2906E1B3 Q26786932-035071BE-8C87-460D-BBF5-818400D5B45D Q26795555-63D030B5-004D-430E-B71A-7620C4217FC1 Q26795556-2395BFD3-EC3C-4026-B605-C5105664DF41

P2860

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

http://www.wikidata.org/entity/Q29547545

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

@ast

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

@en

type

label

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

@ast

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

@en

prefLabel

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

@ast

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

@en

P1433

Q29547545-478865BB-CAA0-4A65-8F7F-215D2E5559DF

P1476

Q29547545-6C93CCFC-2080-4FB0-8BED-90BC7D01FFD4

P2093

Q29547545-0749643E-C28F-46E4-BA50-F603B5DAAB20

Q29547545-078F4C15-CC8F-4CD2-8B88-CE45A9CFB024

Q29547545-094003A1-95E7-49CC-989B-410F4DA71369

Q29547545-0A36DF51-E44D-4F5B-A5A7-092C7B4056ED

Q29547545-17B05076-CE48-4C0F-AFFD-9929F2C62E47

Q29547545-1CB9360F-B230-4F59-A100-C8652EE509E6

Q29547545-21A5490B-BEDD-402D-AC71-4A9D4D73C820

Q29547545-35907AEB-F5D5-43AE-89AC-7BB2F96F5AAD

Q29547545-417F66A7-5196-4736-900A-F4C6A6290F5D

Q29547545-4D7D589F-4392-41B5-98A0-09D6834360BF

P304

Q29547545-E349835E-E99E-4927-A395-EDF482EDD8B9

P31

Q29547545-7B483C67-5F32-4B2D-93DD-335F1E830742

P3181

Q29547545-FA68C71F-177B-4B4B-8E44-4A42782DDBAA

P356

Q29547545-534DBEE9-58E6-462E-A00D-4740F6506E9C

P407

Q29547545-9344785A-A6DB-439C-BD9E-5E89F8590EB0

P433

Q29547545-3A4E8750-2837-4D74-9EB2-49E10B9B5726

P478

Q29547545-66B12A65-3532-44E6-ACFE-D18499BA6CE4

P577

Q29547545-274F1D08-2E47-4BD8-BF91-21C061214F67

P5875

Q29547545-353A5678-179D-40B1-AB53-6A099A96414F

P698

Q29547545-FFB6E2D9-4A5A-412D-A92A-93D29B2BA1C0

P921

Q29547545-047D7A59-B3A6-4B61-AB95-7A54F83DD858

Q29547545-92F1270E-A424-4B24-AD31-84CB8C94B0CC

P3181

P356

P1433

The New England Journal of Medicine

P1476

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

@en

P2093

Ando M

http://www.w3.org/2001/XMLSchema#string

Fujita Y

http://www.w3.org/2001/XMLSchema#string

Gemma A

http://www.w3.org/2001/XMLSchema#string

Hagiwara K

http://www.w3.org/2001/XMLSchema#string

Harada M

http://www.w3.org/2001/XMLSchema#string

Harada T

http://www.w3.org/2001/XMLSchema#string

Hirano H

http://www.w3.org/2001/XMLSchema#string

Inoue A

http://www.w3.org/2001/XMLSchema#string

Isobe H

http://www.w3.org/2001/XMLSchema#string

Kinoshita I

http://www.w3.org/2001/XMLSchema#string

P304

2380-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

331380

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA0909530

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

362

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44698243

http://www.w3.org/2001/XMLSchema#string

P698

20573926

http://www.w3.org/2001/XMLSchema#string

P921